Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD248 inhibitor
- Development stage
- Preclinical
- Lead developer
- University of Alabama at Birmingham
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CD248 inhibitors are a class of experimental therapeutic agents designed to target CD248 (also known as endosialin or tumor endothelial marker 1, TEM1). CD248 is a cell-surface glycoprotein primarily expressed on activated mesenchymal cells, including myofibroblasts, pericytes, and cancer-associated fibroblasts (CAFs), as well as certain malignant cells like sarcomas. Inhibition of CD248 is being explored for its potential to treat fibroproliferative diseases, such as liver fibrosis and pulmonary arterial hypertension (PAH), by modulating TGF-β signaling and reducing aberrant cell proliferation and extracellular matrix remodeling. In oncology, CD248-targeted agents, including antibody-drug conjugates (ADCs) like IgG78-DM1, are being investigated for their ability to disrupt the tumor microenvironment and directly target tumor cells.
- Other names
- Endosialin inhibitorTEM1 inhibitorTEM-1 inhibitorTEM 1 inhibitorCD248 blockadeCD-248 blockadeCD 248 blockade
02
Targets
CD248 (Endosialin)
Beyond the preview
Go deeper on CD248 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD248 inhibitor.